Objective: To investigate the impact of anastomotic leak (AL) on disease recurrence and long-term mortality in patients alive 120 days after curative resection for colonic cancer. Background: There is no solid data as to whether AL after colonic cancer surgery increases the risk of disease recurrence. Methods: This was a nationwide cohort study of 9333 patients, prospectively registered in the database of the Danish Colorectal Cancer Group and merged with data from the Danish Pathology Registry and the National Patient Registry. Multivariable Cox regression analysis was used to adjust for confounding. Results: The incidence of AL was 6.4%, 744 patients died within 120 days. Of the remaining 8589 patients, 861 (10.0%) developed local recurrence with no association to AL [adjusted hazard ratio (HR) = 0.78; 95% confidence interval (CI): 0.55-1.12; P = 0.184]. Distant recurrence developed in 1281 (14.9%) patients and more frequently after AL (adjusted HR = 1.42; 95% CI: 1.13-1.78; P = 0.003). AL was also associated with increased long-term mortality (adjusted HR = 1.20; 95% CI: 1.01-1.44; P = 0.042). In 2841 patients with stage III cancer, AL was associated with both decreased likelihood of receiving adjuvant chemotherapy (adjusted HR = 0.58; 95% CI: 0.45-0.74; P < 0.001) and a delay to initial administration (16 days; 95% CI: 12-20 days; P < 0.001). Conclusions: AL was significantly associated with increased rates of distant recurrence and long-term all-cause mortality. Cancelled or delayed administration of adjuvant chemotherapy may partly account for these findings.
resection for adenocarcinoma, consistent results have demonstrated that AL is associated with an increased rate of local recurrence and long-term mortality, whereas the rate of distant recurrence remains unaffected. [8] [9] [10] [11] In contrast, AL after colonic resection has previously not been associated with higher rates of local or distant recurrence. 9 However, there is evidence that AL reduces both disease-free and overall survivals in patients with colonic cancer. 2, 6 Accordingly, it is essential to distinguish between colonic and rectal cancer surgery because the influence of AL on long-term outcomes seems to differ. The excess long-term mortality after AL could be mediated by increased rates of disease recurrence, higher comorbidity or the influence from factors associated with AL. 12, 13 In this nationwide study on colonic cancer surgery, the primary objective was to investigate the impact of AL on the rates of local and distant disease recurrence and secondary objective was to do it on long-term all-cause mortality. Furthermore, a subgroup analysis was conducted to evaluate the influence of AL on administration of adjuvant chemotherapy (AC) in patients with stage III cancer.
METHODS

Study Population and Variables
This was a nationwide cohort study with data from 3 Danish registers: the prospective database of the Danish Colorectal Cancer Group (DCCG), the Danish Pathology Registry, and the National Patient Registry. Data from these registers were merged to investigate possible associations between AL and long-term outcomes. The primary and secondary outcomes were disease recurrence and all-cause mortality, respectively.
All patients included in the study were recorded in the DCCG database between May 2001 and December 2008 with a first-time diagnosis of colonic adenocarcinoma. The DCCG database is approved by the Danish Data Protection Agency (Ref no. 2000-53-0073) and includes at least 95% of all Danish patients with colorectal cancer. 4 All patients underwent a curative colonic resection with a primary anastomosis without a protecting ostomy. Trained pathologists evaluated all excisional specimens according to the guidelines of the DCCG. The curative resection criteria required at least 2 mm from the tumor to the nonperitonealized resection margin, as evaluated microscopically, and with no tumor growth or distant disease left after completed surgery. The proximal and distal resection margins were examined microscopically when the distance from the tumor to these margins were less than 20 mm.
Data on disease recurrence and overall survival were obtained from the Danish Pathology Registry and the National Patient Registry on November 25, 2010. Recurrent disease was defined according to the DCCG guidelines as local or distant recurrence diagnosed no earlier than 120 days after the index operation. All cases of recurrent disease were confirmed histologically, by diagnostic imaging or surgery. Patients with both local and distant recurrence were classified as distant recurrence. All-cause mortality was exclusively investigated in patients surviving the first 120 postoperative days after primary surgery.
The outcome in patients with stage III colonic cancer may be predicted by the radicality of surgery, administration of AC, and the time to initial administration in patients who receive AC. A post hoc analysis was therefore undertaken to investigate the impact of AL on administration of AC in the group of patients with stage III cancer. In the subset of patients who did receive AC, the influence of AL on time to initial administration was likewise examined. Patients were regarded as having AC if initial administration was achieved before postoperative day 120 according to data from the National Patient Registry. This minimized the risk of bias associated with recurrence developing before the initial administration of AC. During the study period, the standard AC regimen for patients with stage III colonic cancer was a combination of fluorouracil/leucovorin and oxaliplatin. The independent variable of interest, AL, was defined according to the guidelines of the DCCG: "Clinical symptoms suggesting AL and confirmed by contrast enema or computerized tomography" within 60 days from the operation. Patients with AL were identified in the DCCG database or National Patient Registry using the International Classification of Disease (ICD-10) for diagnosis and reoperation codes associated with AL (DT813A, KJWF00).
Relevant and potential confounding covariates were extracted from the DCCG database and the National Patient Registry including age, gender, comorbidity as assessed by the Charlson index, tumor stage (Union for International Cancer control, UICC), type of surgery, surgeon's specialization level, resection of adjacent organs, and perioperative blood transfusion. The Charlson comorbidity index reflects the cumulative increased likelihood of 1-year mortality and was calculated from ICD-10 diagnoses registered in the National Patient Registry before the day of surgery. 14, 15 The comorbidity score was categorized as normal (0), moderate (1), severe (2), and very severe (≥3). 16 The number of patients included in each outcome response was N = 6900 for local recurrence, N = 7315 for distant recurrence, and N = 8164 for all cause mortality. * HR < 1 indicates decreased likelihood of disease recurrence or mortality, whereas HR > 1 indicates increased likelihood of disease recurrence or mortality. †Comorbidity according to Charlson comorbidity index scores of 0 (normal), 1 (moderate), 2 (severe), and ≥ 3 (very severe).
outcome, and administration of AC. Schoenfeld residuals were examined to verify the assumption of proportional hazards. The adjusted influence of AL on the time to initial administration of AC was calculated with multiple linear regression in the subset of patients who did receive AC. All variables were simultaneously included in the multivariable analyses. Status of disease recurrence was then entered as a time-dependent variable to assess the potential mediating role of disease recurrence on the relationship between AL and all-cause mortality. Missing values were disregarded and thus not replaced. Number and percentage of missing values are provided in Table 1 .
The results of the multivariable analyses are presented as hazard ratios (HR) with 95% confidence intervals (CI). All analyses were 2-sided and considered statistically significant if P < 0.050. Data were analyzed with SPSS Statistics Version 20 (IBM Corp, Armonk, NY).
Meta-analysis of published data on the relationship between AL and distant disease recurrence was performed using the Mantel -Haenszel random-effects model (Review Manager, Version 5.1, Copenhagen, Denmark: the Nordic Cochrane Centre, the Cochrane Collaboration), updating (September 2013) the systematic review from Mirnezami et al 9 including the present data. A sensitivity analysis was performed removing individual studies in a serial fashion to determine the influence of each study on the combined OR estimate and 95% CI. 
Disease Recurrence
The number of patients with local and distant recurrence were 861 (10.0%) and 1281 (14.9%), respectively. The latter group included 283 (3.3%) patients with both local and distant recurrence. The number of disease-free patients alive at the end of follow-up was 4849 (56.5%). The median time to diagnosis of local and distant recurrence was 1.2 years (IQR: 0.6-2.4 years) and 1.5 years (IQR: 0.9-2.5 years), respectively. In the univariable analysis, AL was not associated with local recurrence [HR = 0.92 (95% CI: 0.66-1.29; P = 0.638)], which was confirmed in the multivariable analysis [HR = 0.78 (95% CI: 0.55-1.12; P = 0.184)]. Covariates with a significant influence on local recurrence were age, tumor stage, surgical approach, and surgeon's specialization level ( Table 2 ). In contrast to local recurrence, there was a significant association between AL and distant recurrence in both the univariable analysis [HR = 1.49 (95% CI: 1.20-1.85; P < 0.001] (Fig. 2 ) and the multivariable analysis [HR = 1.42 (95% CI: 1.13-1.78; P = 0.003] ( Table 2 ). In addition, gender, age, comorbidity, tumor stage, surgical priority, and extracolonic organ resection were significantly associated with distant recurrence ( Table 2) .
The association between AL and distant recurrence was put in context of previous published studies, updating a meta-analysis by Mirnezami et al. 9 Four additional studies were included in addition to the present data. 6, [18] [19] [20] The Forest plot showed a significant association between AL and development of distant recurrence (OR = 1.38; 95% CI: 1.05-1.81; P = 0.02; Fig. 3 ). The sensitivity analysis rendered a nonsignificant association between AL and distant recurrence in the combined estimate after exclusion of the study by Law et al 20 (OR = 1.26; 95% CI: 0.99-1.60; P = 0.06) or the present study (OR = 1.35; 95% CI: 0.97-1.89; P = 0.08). The analysis included a subset of patients with stage III colonic cancer who received adjuvant chemotherapy within 120 days from the index operation, N = 1725. The Intercept in this model was 44 days (95% CI: 42-47 days) and predicts the time to AC when all variables take the reference value. The coefficients were rounded to whole numbers (days) and estimate the change in time to AC given a change from the reference value.
* Comorbidity according to the Charlson Comorbidity Index scores of 0 (normal), 1 (moderate), 2 (severe), and ≥3 (very severe).
Long-Term All-Cause Mortality
AL was significantly associated with increased all-cause mortality in the multivariable analysis [HR = 1.20 (95% CI: 1.01-1.44; P = 0.042)]. Covariates that reached statistical significance were gender, age, comorbidity, tumor stage, surgical procedure and priority, surgeon's specialization level, extracolonic organ resection, and blood transfusion ( Table 2) .
In contrast to local recurrence, distant recurrence was significantly (P < 0.001) associated with all-cause mortality (Fig. 4) . Inclusion of recurrence status as a time-dependent variable in the multivariable model eliminated the impact of AL on mortality [HR = 1.10 (95% CI: 0.92-1.32; P = 0.289)].
Administration of Adjuvant Chemotherapy in Stage III Cancer Patients
In the subgroup of patients with stage III disease, administration of AC was initiated in 1725 of 2841 (60.7%) patients within 120 days. Patients with AL were less likely to receive AC according to both the univariable [HR = 0.65 (95% CI: 0.51-0.83; P < 0.001)] and the multivariable models [HR = 0.58 (95% CI: 0.45-0.74; P < 0.001] ( Table 3 and Fig. 5 ). In addition, the time to initial administration of AC was median 59 days (IQR: 48-82 days) after surgery for patients with AL compared with 43 days (IQR: 35-54 days) in patients without AL (P < 0.001). Multiple linear regression analysis confirmed that administration of AC was initiated 16 days (95% CI: 12-20 days; P < 0.001) later in patients with AL compared with patients without AL ( Table 4 ).
Administration of AC in patients with AL was not associated with a reduction in distant recurrence but a significant reduction in allcause mortality (Figs. 6A, C) . Administration of AC beyond 55 days from primary surgery was not associated with a significant reduction in long-term mortality [HR = 0.88 (95% CI: 0.68-1.02] ( Table 5 ). The rates of distant recurrence and mortality in patients receiving AC within day 55 were comparable between patients with and without AL (Figs. 6B, D) .
DISCUSSION
This nationwide study demonstrates an inferior oncological outcome in patients who develop AL after curative resection for colonic cancer and survive the first critical postoperative phase. This is reflected by an increased rate of distant recurrence and therefore a continuing excess mortality.
The distinct finding, that AL was associated with a significant increase in distant recurrence, provides new insight into the negative implications of AL in patients with colonic cancer. The issue was recently addressed in a meta-analysis in which Mirnezami et al were unable to confirm a relationship between AL and distant recurrence (overall OR = 1.38; 95% CI: 0.96-1.99; P = 0.083). 9 However, the meta-analysis included pooled data from studies on both colonic 8 and rectal cancer surgery, 8, 10, 11 as well as mixed colorectal cancer surgery. [21] [22] [23] [24] The update of the meta-analysis by Mirnezami et al including the present data suggests a relationship between AL and development of distant recurrence. The sensitivity analysis indicates that the large cohort in the present study may drive the outcome of the meta-analysis to become statistically significant. A fuller metaanalysis including a subgroup analysis of patients with colonic cancer is warranted to address the robustness of the conclusion that AL increases the risk of distant recurrence in patients with colonic cancer. The unadjusted results from the meta-analysis could also be subjected to confounding because advanced tumor stage, emergency surgery, and comorbidity were strong predictors for distant recurrence in the present study. Nevertheless, the association between AL and distant recurrence remained significant in the multivariable analysis. A limitation of this finding is the competing risk of mortality in patients dying before a potential recurrence.
The present study included patients from all Danish departments conducting colorectal surgery during the study period and was further strengthened by an almost complete and unselected compilation of data merged from 3 different population-based national registers. There was a long follow-up period extending beyond the traditional 2 years used for assessing recurrence status. However, radiological and endoscopic follow-up was not performed routinely raising the risk that some patients with recurrence may have remained unrecognized despite the study design with 3 independent sources of data. Another limitation is the allocation of patients with both local and distant recurrence to the group of patients with distant recurrence.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. This could potentially limit the analyses of local recurrence because a subset of these patients was thus not included in the analyses. The purpose was to avoid an overinterpretation of the impact of local recurrence and was supported by the finding of equal mortality rates in any patient with distant metastasis compared with patients with local recurrence (Fig. 4) .
Although AL increased the rate of distant recurrence, no influence on local recurrence was observed. This is in agreement with other reports on colonic surgery but differs from rectal surgery. [7] [8] [9] The finding illustrates the importance of analyzing long-term outcome in patients with colonic and rectal cancer separately. The incidence of local recurrence is reported lower after resection of colonic cancer as compared with rectal cancer, possibly because local recurrence in colonic cancer may remain undiagnosed until symptomatic distant metastases develop. 25 In addition, data from a human study demonstrated significantly higher cytokine levels, especially interleukin-8, in the region around rectal anastomoses as compared with colonic anastomoses. 26 interleukin-8 promotes proliferation and metastasis of colorectal cancer cells and may impair anastomotic healing. 26, 27 Interestingly, local recurrence did not affect the overall mortality. This somewhat surprising finding was also reported in a randomized trial on the effect of preoperative radiotherapy in rectal cancer surgery, where a significant reduction in local recurrence from 8.2% to 2.4% was not paralleled by a reduction in mortality. 28 The present cohort of more than 9000 unselected patients with colonic cancer allowed a thorough analysis of the association of AL with local recurrence including adjustment for confounders. The findings confirm that AL does not predict development of local recurrence in patients with colonic cancer.
Previously, the impact of AL on long-term mortality has been analyzed in different ways. Five-year overall survival was decreased in patients with AL, 2,6 but these studies included patients dying within 30 days after surgery. To avoid this potential overlap of short-and long-term mortality, patients who died within the first 120 days were excluded from the present analysis. It was subsequently observed that patients with AL were still at increased risk of a fatal outcome. Adjustment for comorbidity, a known predictor for reduced survival in patients with colorectal cancer, 29 did not alter this conclusion. Interestingly, the influence of AL on mortality did not persist with addition of recurrence status to the multivariable analysis. This suggests that the effect of AL on long-term mortality was mediated by an increased rate of distant recurrence.
It remains to be established which mechanisms promote distant recurrence in patients with AL. To address this, the impact of AL on administration of AC in patients with stage III colonic cancer was analyzed. AC increases overall survival by about 30% compared with surgery alone 30, 31 and is thus important in these high-risk patients. Severe inflammation due to peritonitis and septicemia after AL may contribute to the metastatic cascade explaining the association between AL and distant recurrence in the present study. 32 Furthermore, AL was strongly associated with cancelled administration of AC in the subset of patients with stage III colonic cancer. Similar findings were reported in patients with AL after low anterior resection. 33 Recently, El Shayeb et al 34 demonstrated that comorbidity and advanced age were main reasons physicians did not recommend AC. Here, the association between AL and administration of AC was consistent after adjustment for confounding variables including age and comorbidity. The authors did further conclude that reasons for patient refusal were mostly unknown. 34 Postoperative complications including AL could influence these patients' attitude toward AC.
AL was also associated with a significant delay in initial administration of AC. The delay persisted after adjustment for confounding variables and postponed the initial administration to 8 weeks after primary surgery. When AC was initiated beyond day 55 after primary surgery, there was no significant reduction in mortality compared with patients who did not receive AC. Biagi et al 35 recently addressed the consequences of delayed AC, reporting a 14% decrease of both overall and disease-free survival for every 4 weeks' postponement of initial administration. The present data do not support late onset administration of AC in patients with AL after curative surgery for stage III colonic cancer.
CONCLUSIONS
This study demonstrated increased mortality rates in patients surviving the first critical phase after AL. A robust association between AL and distant recurrence was observed suggesting that the poor long-term prognosis in patients with AL was promoted by increased metastatic activity. Cancelled or delayed administration of AC because of AL may partly account for these findings.
